Respiratory syncytial virus: infection, detection, and new options for prevention and treatment
Respiratory syncytial virus (RSV) infection is a significant cause of hospitalization of children
in North America and one of the leading causes of death of infants less than 1 year of age …
in North America and one of the leading causes of death of infants less than 1 year of age …
Respiratory syncytial virus: the influence of serotype and genotype variability on clinical course of infection
S Vandini, C Biagi, M Lanari - International journal of molecular sciences, 2017 - mdpi.com
Respiratory syncytial virus (RSV) belongs to the recently defined Pneumoviridae family,
Orthopneumovirus genus. It is the leading cause of acute bronchiolitis and one of the most …
Orthopneumovirus genus. It is the leading cause of acute bronchiolitis and one of the most …
Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody
JS McLellan, M Chen, S Leung, KW Graepel, X Du… - Science, 2013 - science.org
The prefusion state of respiratory syncytial virus (RSV) fusion (F) glycoprotein is the target of
most RSV-neutralizing activity in human sera, but its metastability has hindered …
most RSV-neutralizing activity in human sera, but its metastability has hindered …
Generation and characterization of ALX-0171, a potent novel therapeutic nanobody for the treatment of respiratory syncytial virus infection
L Detalle, T Stohr, C Palomo, PA Piedra… - Antimicrobial agents …, 2016 - Am Soc Microbiol
Respiratory syncytial virus (RSV) is an important causative agent of lower respiratory tract
infections in infants and elderly individuals. Its fusion (F) protein is critical for virus infection. It …
infections in infants and elderly individuals. Its fusion (F) protein is critical for virus infection. It …
Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes
JS McLellan, Y Yang, BS Graham, PD Kwong - Journal of virology, 2011 - Am Soc Microbiol
Respiratory syncytial virus (RSV) invades host cells via a type I fusion (F) glycoprotein that
undergoes dramatic structural rearrangements during the fusion process. Neutralizing …
undergoes dramatic structural rearrangements during the fusion process. Neutralizing …
Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease
MF Delgado, S Coviello, AC Monsalvo, GA Melendi… - Nature medicine, 2009 - nature.com
Respiratory syncytial virus (RSV) is a leading cause of hospitalization in infants. A formalin-
inactivated RSV vaccine was used to immunize children and elicited nonprotective …
inactivated RSV vaccine was used to immunize children and elicited nonprotective …
Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors
MSA Gilman, CA Castellanos, M Chen… - Science …, 2016 - science.org
Respiratory syncytial virus (RSV) causes substantial morbidity and mortality in young
children and the elderly. There are currently no licensed RSV vaccines, and passive …
children and the elderly. There are currently no licensed RSV vaccines, and passive …
Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers
KA Swanson, EC Settembre… - Proceedings of the …, 2011 - National Acad Sciences
Respiratory syncytial virus (RSV), the main cause of infant bronchiolitis, remains a major
unmet vaccine need despite more than 40 years of vaccine research. Vaccine candidates …
unmet vaccine need despite more than 40 years of vaccine research. Vaccine candidates …
Transient opening of trimeric prefusion RSV F proteins
MSA Gilman, P Furmanova-Hollenstein… - Nature …, 2019 - nature.com
The respiratory syncytial virus (RSV) F glycoprotein is a class I fusion protein that mediates
viral entry and is a major target of neutralizing antibodies. Structures of prefusion forms of …
viral entry and is a major target of neutralizing antibodies. Structures of prefusion forms of …
Structural basis of respiratory syncytial virus neutralization by motavizumab
JS McLellan, M Chen, A Kim, Y Yang… - Nature structural & …, 2010 - nature.com
Motavizumab is∼ tenfold more potent than its predecessor, palivizumab (Synagis), the FDA-
approved monoclonal antibody used to prevent respiratory syncytial virus (RSV) infection …
approved monoclonal antibody used to prevent respiratory syncytial virus (RSV) infection …